The FDA recently approved Fleqsuvy (baclofen) oral suspension, a muscle relaxant, for the treatment of spasticity resulting from multiple sclerosis and for patients with spinal cord injuries and other spinal cord diseases.
Spinal cord injuries can occur in workers’ comp, leading to muscle spasms that require pharmaceutical care, meaning Fleqsuvy could potentially appear in workers’ comp claims.
According to the drug label, Fleqsuvy is not indicated for the treatment of skeletal muscle spasms resulting from rheumatic disorders, and abrupt discontinuation of Fleqsuvy can result in serious adverse reactions, including death. Dosage should be reduced slowly.
Fleqsuvy can cause drowsiness, dizziness, weakness, and sedation, and patients should avoid operating motor vehicles and heavy machinery, as well as alcohol and other central nervous system (CNS) depressants.